Mesa Labs insider: 1,949 RSUs vested; 3,810 RSUs remain unvested

Rhea-AI Filing Summary

Shiraz Ladiwala, a director of Mesa Laboratories, received restricted stock unit vestings and holds common stock. On August 15, 2025, 1,949 RSUs vested and were reported as acquired resulting in 1,949 shares delivered at $0 per share. Additionally, 3,810 RSUs granted on the same date were reported as unvested and remain scheduled to vest on August 15, 2026, representing an additional 3,810 shares. After the vested delivery, the reporting person beneficially owned 5,023 shares of Mesa Laboratories common stock. The Form 4 was filed by one reporting person and lists the reporting person as a director. The filing was signed under power of attorney on August 15, 2025.

Insights

Securities Analyst

TL;DR: Routine insider vesting resulted in 1,949 shares delivered and 3,810 RSUs remaining unvested; no sale or external transaction noted.

The filing documents standard equity compensation activity: 1,949 restricted stock units vested and were converted into shares at no cost to the director, raising beneficial ownership to 5,023 shares. A separate grant of 3,810 RSUs remains subject to future vesting on 08/15/2026. There is no cash transaction, sale, or transfer that would signal immediate liquidity or diversification by the insider. From an investor-impact perspective, this is a routine disclosure of compensation-related share issuance rather than a market-moving event.

Corporate Governance Expert

TL;DR: This Form 4 reports scheduled equity compensation vesting for a director; it aligns with typical executive/board award schedules.

The report indicates compliance with Section 16 reporting: vested RSUs converted to 1,949 shares and an additional 3,810 RSUs remain outstanding with a one-year vesting horizon. The director is identified and the form was executed via power of attorney. There are no indications of unusual timing, accelerated vesting, or related-party transactions disclosed here. Governance implications are limited as this reflects standard equity compensation administration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ladiwala Shiraz Shabanali

(Last) (First) (Middle)

C/O THERMO FISHER SCIENTIFIC INC.

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		1,949	A	$0	5,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units - 5	(1)	08/15/2025		M			1,949	(2)	(3)	Common Stock	1,949	$0	0	D
Restricted Stock Units - 6	(1)	08/15/2025		A		3,810		(4)	(3)	Common Stock	3,810	$0	3,810	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested on August 15, 2025

3. Not Applicable

4. RSUs that vest on August 15, 2026

	John Sakys under Power of Attorney by Shiraz Ladiwala	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did the Form 4 report for Mesa Laboratories (MLAB)?

The Form 4 reports that director Shiraz Ladiwala had 1,949 RSUs vest on 08/15/2025, which were converted to shares, and holds an additional 3,810 RSUs scheduled to vest on 08/15/2026.

How many Mesa Laboratories shares does the reporting person beneficially own after the transaction?

Following the reported delivery of vested RSUs, the reporting person beneficially owned 5,023 shares of common stock.

Was there a sale or purchase involving cash in this Form 4 filing for MLAB?

No. The filing shows RSUs vesting and delivery of shares at a reported price of $0; there is no cash purchase or sale reported.

When are the unvested RSUs scheduled to vest according to the filing?

The additional 3,810 RSUs are scheduled to vest on 08/15/2026.

Who signed the Form 4 for the reporting person?

The Form 4 was signed under power of attorney by John Sakys on behalf of Shiraz Ladiwala on 08/15/2025.